Genmab A/S (GE9) Financial Statements
Genmab A/S Financial Overview
Genmab A/S's market cap is currently $31.28B. The company's EPS TTM is $12.80; its P/E ratio is 45.64; Genmab A/S is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $3.13. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 3.86B | $ 21.53B | $ 16.47B | $ 14.51B | $ 8.48B |
| Gross Profit | $ 3.54B | $ 20.54B | $ 16.25B | $ 14.51B | $ 8.48B |
| Operating Income | $ 1.30B | $ 7.00B | $ 5.32B | $ 6.30B | $ 2.95B |
| EBITDA | $ 1.37B | $ 9.70B | $ 5.99B | $ 7.33B | $ 3.27B |
| Net Income | $ 999.19M | $ 7.84B | $ 4.35B | $ 5.45B | $ 2.96B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.71B | $ 21.10B | $ 28.14B | $ 22.32B | $ 19.34B |
| Total Assets | $ 12.84B | $ 45.81B | $ 35.29B | $ 30.12B | $ 24.63B |
| Total Debt | $ 5.55B | $ 1.03B | $ 770.00M | $ 597.00M | $ 425.00M |
| Net Debt | $ 3.84B | $ -8.83B | $ -14.10B | $ -9.30B | $ -8.53B |
| Total Liabilities | $ 7.01B | $ 9.11B | $ 3.68B | $ 2.84B | $ 2.43B |
| Stockholders' Equity | $ 5.83B | $ 36.70B | $ 31.61B | $ 27.28B | $ 22.20B |
| Cash Flow | |||||
| Free Cash Flow | $ 1.19B | $ 7.58B | $ 7.00B | $ 3.60B | $ 1.98B |
| Operating Cash Flow | $ 1.23B | $ 7.77B | $ 7.38B | $ 3.91B | $ 2.23B |
| Investing Cash Flow | $ -5.86B | $ -9.91B | $ -1.28B | $ -2.76B | $ -961.00M |
| Financing Cash Flow | $ 4.97B | $ -3.92B | $ -606.00M | $ -789.00M | $ -420.00M |
Currency in DKK
